

JAN 08 2003

Atty. Dkt. No. MSA-004.01 (20974-401)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gordon W. DUFF *et al.*

Title: Therapeutics and Diagnostics Based on a Novel IL-1B Mutation

Appl. No. 09/247,874

Filing Date: February 10, 1999

Examiner: R. Schnizer

Art Unit: 1635

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action Dated July 30, 2002 containing a Notice to Comply With Requirements for Applications Containing Sequence Disclosures, please amend the application as follows:

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 37, line 37 through page 38, line 19 and replace it with the following paragraph:

2. PCR 5' Nuclease Method. Further screening was carried out using the TAQMAN®fluorogenic probe-based technique wherein a mismatched oligonucleotide probe spanning the allele is displaced, but a match oligonucleotide probe is digested by the 5' nuclease activity of the TAQMAN® polymerase. These two states can be detected using probes that are differentially labeled with fluorogenic labels (e.g. tetra-chloro-